[ad_1] A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company’s biggest drug category. Biogen booked sales of $2.39…
[ad_1] In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. Pavlo Gonchar | SOPA Images | Lightrocket | Getty Images Shares of Sage Therapeutics fell more than 50% on Monday after the Food and Drug Administration approved the biotech company’s oral drug zuranolone…
[ad_1] As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. Specifically, analyst Jay Olson called out companies such as Biogen , Karuna Therapeutics and Crispr Therapeutics , among others. “Our analysis shows Genetic Medicine and…
